Skip Navigation


European Heart Journal Advance Access originally published online on July 3, 2006
European Heart Journal 2006 27(15):1767-1768; doi:10.1093/eurheartj/ehl128
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
27/15/1767    most recent
ehl128v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Jørgensen, E.
Right arrow Articles by Kastrup, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jørgensen, E.
Right arrow Articles by Kastrup, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Epo ‘cytokine-doping’ of heart disease patients, will it work?

Erik Jørgensen1,*, Lene Bindslev2, Rasmus Sejersten Ripa1 and Jens Kastrup1,2

1 Cardiac Catheterisation Laboratory, The Heart Centre, University Hospital Rigshospitalet, Copenhagen, DK-2100, Denmark
2 Cardiac Stem Cell Research Laboratory, University Hospital Rigshospitalet, Copenhagen, Denmark

* Corresponding author. Tel: +45 35453693; fax: +45 35452705. E-mail address: erikj@rh.dk

This editorial refers to ‘Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy’{dagger} by S. Hamed et al., on page 1876

The first 10% of the full text of this article appears below.

Erythropoietin (EPO) is a cytokine for erythrocyte precursors in the bone marrow, and the glycoprotein hormone that regulates red blood cell production. EPO is mainly produced in the kidney and production is induced by hypoxia/ischaemia. The main transcriptional factor is HIF-1, which is also induced by hypoxia/ischaemia in myocardial cells. EPO is also expressed in the heart. However, its expression may only be brief, it has in fact only been shown 24–48 h after permanent coronary artery occlusion in mice hearts.1

EPO was purified from urine for therapeutic use in the 1970s and recombinant EPO (rEPO) has been available since . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy
Saher Hamed, Iris Barshack, Galia Luboshits, Dov Wexler, Varda Deutsch, Gad Keren, and Jacob George
EHJ 2006 27: 1876-1883. [Abstract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
M. Minetti, L. Agati, and W. Malorni
The microenvironment can shift erythrocytes from a friendly to a harmful behavior: Pathogenetic implications for vascular diseases
Cardiovasc Res, July 1, 2007; 75(1): 21 - 28.
[Abstract] [Full Text] [PDF]